JP2020505942A - フェニルアラニンアンモニアリアーゼポリペプチド - Google Patents

フェニルアラニンアンモニアリアーゼポリペプチド Download PDF

Info

Publication number
JP2020505942A
JP2020505942A JP2019543213A JP2019543213A JP2020505942A JP 2020505942 A JP2020505942 A JP 2020505942A JP 2019543213 A JP2019543213 A JP 2019543213A JP 2019543213 A JP2019543213 A JP 2019543213A JP 2020505942 A JP2020505942 A JP 2020505942A
Authority
JP
Japan
Prior art keywords
engineered
polypeptide
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019543213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505942A5 (enExample
Inventor
チンピン チェン，
チンピン チェン，
ウィリアム ケイシー ハロウズ，
ウィリアム ケイシー ハロウズ，
ニコラス ジェイ． アガード，
ニコラス ジェイ． アガード，
オスカー アルビゾ，
オスカー アルビゾ，
ニッキ デラス，
ニッキ デラス，
ジャルト ダブリュー． ユイスマン，
ジャルト ダブリュー． ユイスマン，
ジョン ジョセフ ニコルス，
ジョン ジョセフ ニコルス，
Original Assignee
コデクシス， インコーポレイテッド
コデクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コデクシス， インコーポレイテッド, コデクシス， インコーポレイテッド filed Critical コデクシス， インコーポレイテッド
Publication of JP2020505942A publication Critical patent/JP2020505942A/ja
Publication of JP2020505942A5 publication Critical patent/JP2020505942A5/ja
Priority to JP2022080791A priority Critical patent/JP2022103296A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2019543213A 2017-02-13 2018-02-12 フェニルアラニンアンモニアリアーゼポリペプチド Pending JP2020505942A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022080791A JP2022103296A (ja) 2017-02-13 2022-05-17 フェニルアラニンアンモニアリアーゼポリペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762458232P 2017-02-13 2017-02-13
US62/458,232 2017-02-13
US201762565555P 2017-09-29 2017-09-29
US62/565,555 2017-09-29
PCT/US2018/017773 WO2018148633A1 (en) 2017-02-13 2018-02-12 Engineered phenylalanine ammonia lyase polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022080791A Division JP2022103296A (ja) 2017-02-13 2022-05-17 フェニルアラニンアンモニアリアーゼポリペプチド

Publications (2)

Publication Number Publication Date
JP2020505942A true JP2020505942A (ja) 2020-02-27
JP2020505942A5 JP2020505942A5 (enExample) 2021-03-18

Family

ID=63106144

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543213A Pending JP2020505942A (ja) 2017-02-13 2018-02-12 フェニルアラニンアンモニアリアーゼポリペプチド
JP2022080791A Pending JP2022103296A (ja) 2017-02-13 2022-05-17 フェニルアラニンアンモニアリアーゼポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022080791A Pending JP2022103296A (ja) 2017-02-13 2022-05-17 フェニルアラニンアンモニアリアーゼポリペプチド

Country Status (15)

Country Link
US (4) US10995329B2 (enExample)
EP (1) EP3579867A4 (enExample)
JP (2) JP2020505942A (enExample)
KR (1) KR102573324B1 (enExample)
CN (1) CN110573175A (enExample)
AU (1) AU2018217495B2 (enExample)
BR (1) BR112019016634A2 (enExample)
CA (1) CA3051262A1 (enExample)
IL (1) IL268226A (enExample)
MX (1) MX2019009615A (enExample)
MY (1) MY196740A (enExample)
NZ (1) NZ755628A (enExample)
PH (1) PH12019501705A1 (enExample)
SG (1) SG11201906880VA (enExample)
WO (1) WO2018148633A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. Engineered tyrosine ammonia lyase
WO2021168060A1 (en) * 2020-02-19 2021-08-26 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
CN112355034B (zh) * 2020-11-17 2021-08-06 同济大学 基于水热钙离子调配的有机固体废弃物无害化预处理方法
CN115518691B (zh) * 2022-10-14 2023-11-21 天津大学 一种具有类漆酶活性的人工酶及制备方法和应用
AU2024289192A1 (en) 2023-07-06 2026-01-08 Perseo Pharma Ag Method for immobilization of proteins
EP4739349A1 (en) 2023-07-06 2026-05-13 Perseo Pharma AG Functionalized compositions comprising an engineered phenylalanine ammonia lyase (pal)
WO2026163257A1 (en) 2025-01-29 2026-08-06 Dr. Schär S.P.A. Microorganism, production method and use for the treatment of phenylketonuria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536759A (ja) * 2007-08-17 2010-12-02 ビオマリン プハルマセウトイカル インコーポレイテッド 原核生物フェニルアラニンアンモニアリアーゼの組成物、及び、その組成物を用いる癌の治療方法
JP2016516428A (ja) * 2013-04-18 2016-06-09 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK75593D0 (enExample) * 1993-06-25 1993-06-25 Novo Nordisk As
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CA2191718A1 (en) 1994-06-03 1995-12-14 Randy M. Berka Phosphonyldipeptides useful in the treatment of cardiovascular diseases
ATE294871T1 (de) 1994-06-30 2005-05-15 Novozymes Biotech Inc Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1717322B1 (en) 1997-01-17 2012-07-18 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
CA2326835A1 (en) 1998-04-02 1999-10-14 Tellus Genetic Resources, Inc. A method for obtaining a plant with a genetic lesion in a gene sequence
CN1314911A (zh) 1998-05-01 2001-09-26 麦克西根股份有限公司 用dna改组优化害虫抗性基因
JP2002517995A (ja) 1998-06-17 2002-06-25 マキシジェン， インコーポレイテッド 所望の特性を有するポリヌクレオチドを生成するための方法
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
EP1104459A1 (en) 1998-08-12 2001-06-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
AU6510799A (en) 1998-10-07 2000-04-26 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
JP2002534965A (ja) 1999-01-19 2002-10-22 マキシジェン， インコーポレイテッド 所望の特徴を有する文字ストリング、ポリヌクレオチドおよびポリペプチドを作製するための方法
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
SG121902A1 (en) 2000-01-11 2006-05-26 Maxygen Inc Integrated systems for diversity generation and screening
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
AU2001249811B2 (en) 2000-04-03 2006-06-08 Maxygen, Inc. Subtilisin variants
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
EP2315145B1 (en) 2002-03-01 2015-11-25 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US8003356B2 (en) 2004-04-20 2011-08-23 E. I. Du Pont De Nemours And Company Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
WO2009102901A1 (en) 2008-02-12 2009-08-20 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
ES2705694T3 (es) 2008-06-13 2019-03-26 Codexis Inc Método de síntesis de variantes de polinucleótidos
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
WO2013003290A1 (en) 2011-06-28 2013-01-03 Codexis, Inc. Protein variant generation by region shuffling
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
CA2815341A1 (en) 2010-11-05 2012-05-10 Basf Plant Science Company Gmbh Methods for increasing yield and fine chemical production in plants
WO2012122333A1 (en) 2011-03-08 2012-09-13 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Microbial conversion of glucose to styrene and its derivatives
US20130005012A1 (en) 2011-06-23 2013-01-03 Phytogene, Inc. Enzymatic system for monomer synthesis
US20150050658A1 (en) 2012-03-15 2015-02-19 Codexix, Inc. Gene shuffling methods
RU2695146C2 (ru) 2013-01-31 2019-07-22 Кодексис, Инк. Способы, системы и программное обеспечение для идентификации биомолекул со взаимодействующими компонентами
DK3049973T3 (en) 2013-09-27 2018-10-22 Codexis Inc AUTOMATED SCREENING OF ENZYM VARIENTS
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536759A (ja) * 2007-08-17 2010-12-02 ビオマリン プハルマセウトイカル インコーポレイテッド 原核生物フェニルアラニンアンモニアリアーゼの組成物、及び、その組成物を用いる癌の治療方法
JP2016516428A (ja) * 2013-04-18 2016-06-09 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOL. GENET. METAB., vol. 99, no. 1, JPN6018011205, January 2010 (2010-01-01), pages 4 - 9, ISSN: 0004946333 *

Also Published As

Publication number Publication date
US20210222145A1 (en) 2021-07-22
EP3579867A4 (en) 2021-03-10
KR102573324B1 (ko) 2023-08-30
CN110573175A (zh) 2019-12-13
IL268226A (en) 2019-09-26
EP3579867A1 (en) 2019-12-18
KR20190117577A (ko) 2019-10-16
SG11201906880VA (en) 2019-08-27
CA3051262A1 (en) 2018-08-16
MX2019009615A (es) 2019-10-14
JP2022103296A (ja) 2022-07-07
AU2018217495B2 (en) 2021-03-04
US20180230448A1 (en) 2018-08-16
WO2018148633A1 (en) 2018-08-16
MY196740A (en) 2023-05-03
NZ755628A (en) 2023-09-29
AU2018217495A1 (en) 2019-08-08
US10995329B2 (en) 2021-05-04
PH12019501705A1 (en) 2020-07-06
BR112019016634A2 (pt) 2020-04-07
US20230295598A1 (en) 2023-09-21
US20230295599A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US11913045B2 (en) Engineered phenylalanine ammonia lyase polypeptides
US20230295599A1 (en) Engineered phenylalanine ammonia lyase polypeptides
BR112015026160B1 (pt) Polipeptídeo engenheirado com atividade de fenilalanina amônia-liase,sequência de polinucleotídeo, vetor de expressão, célula hospedeira transformada, método para produzir um polipeptídeo de pal engenheirado em uma célula hospedeira, composição, e, uso de uma composição

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221114

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221223

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221227